专利号:US-9359370-B2 优先权日:2008-07-08 标题 :Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof 发明人:WANG YINXIANG; XIE GUOJIAN; DING LIEMING; TAN FENLAI; HU YUNYAN; HE WEI; HAN BIN; LONG WEI; LIU YONG; Ai haima; DAVIS CHARLES; ZHANG DON 权利人:BETA PHARMA INC 摘要:The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.
专利号:WO-2007138613-A3 优先权日:2006-05-25 标题 :A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride 发明人:CHANDREGOWDA VENKATESHAPPA; RAO GUDAPATI VENKATESWARA; KUSH ANIL KUMAR; REDDY GOUKANAPALLI CHANDRASEKARA 权利人:VITTAL MALLYA SCIENT RES FOUND; CHANDREGOWDA VENKATESHAPPA; RAO GUDAPATI VENKATESWARA; KUSH ANIL KUMAR; REDDY GOUKANAPALLI CHANDRASEKA 摘要:The present invention provides a process for synthesizing [6,7-bis(2-methoxyethoxy)quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride (Erlitinib Hydrochloride) having the formula (I) comprising reacting 3,4-dihydroxy benzaldehyde with bromo derivative of ethyl methyl ether to obtain 3,4-bis(2-methoxyethoxy)benzaldehyde having formula (III). This is converted to give 3,4- bis (2-methoxyethoxy)-benzonitrile which on furthur nitration we obtain 4,5- bis (2-methoxyethoxy)-2-nitrobenzonitrile which on nitro reduction we get 2-amino-4,5-bis(2-methoxyethoxy)benzonitrile. Formylation of this compound yields N'-[2-cyano-4,5-bis(2methoxyethoxy)phenyl]-N,N-dimethylformamidine. Coupling of this formamidine with 3-ethynyl aniline gives erlotinib free base. On furthur treatment of this free base with methanolic/ethanolic hydrochloric acid gives us erlotinib hydrochloride.
专利号:US-2022118094-A1 优先权日:2019-02-21 标题:Synthesis of biomimetic cell wall structure 发明人:WANG YONG; SHI PENG 权利人:PENN STATE RES FOUND 摘要:The present invention relates generally to methods of generating a biomimetic cell wall (BCW) on a target surface, compositions comprising the BCW, and methods of use of the compositions, including biomedical applications of the BCW coated compositions.
专利号:US-12441733-B2 优先权日:2018-03-26 标题:Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors 发明人:ARISTA LUCA; HEBACH CHRISTINA; HOLLINGWORTH GREGORY JOHN; HOLZER PHILIPP; IMBACH-WEESE PATRICIA; LORBER JULIEN; MACHAUER RAINER; SCHMIEDEBERG NIKO; VULPETTI ANNA; ZOLLER THOMAS 权利人:NOVARTIS AG 摘要:The invention relates to compounds of the formulae (I), (III), (IIIa), (XXIa), (XXIII), and/or (XLVI)or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
专利号:US-8133999-B2 优先权日:2003-07-30 标题 :Process for preparation of 6, 7-bis(2-methoxyethoxy) quinazolin-4-one 发明人:NISHINO SHIGEYOSHI; HIROTSU KENJI; SHIMA HIDETAKA; ODA HIROYUKI; SUZUKI SHINOBU 权利人:NISHINO SHIGEYOSHI; HIROTSU KENJI; SHIMA HIDETAKA; ODA HIROYUKI; SUZUKI SHINOBU; UBE INDUSTRIES 摘要:6,7-Bis(2-methoxyethoxy)quinazolin-4-one of formula (5) useful in synthesis of an anti-cancer drug can be prepared by a reaction of ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate of formula (4) with an orthoformic acid in the presence of an ammonium acetate:
专利号:US-11130764-B2 优先权日:2017-02-17 标题 :Analogs of vincamine and uses thereof 发明人:HUIGENS III ROBERT WILLIAM; NORWOOD IV VERRILL M; LUESCH HENDRIK 权利人:UNIV FLORIDA 摘要:The present disclosure provides compounds of any one of Formulae (I′), (I), (IA), (II′), (II), (IIA), (IIIA), (III″), (III′), (III), (IIIA), (IV), (V′), (V), (VI), (VII), (VIII′), (VIII), (IX′), (IX), and (X). The compounds described herein may be useful in treating and/or preventing a broad range of diseases (e.g., proliferative disease (e.g., cancers (e.g., non-small cell lung cancer, or glioma), inflammatory diseases, autoimmune diseases), CNS disorder (e.g., drug addiction), metabolic disorder (e.g., diabetes), or infectious disease (e.g., bacterial infection or parasitic infection (e.g., malaria))). Also provided in the present disclosure are pharmaceutical compositions, methods of synthesis of a compound described herein, kits, methods, and uses including or using a compound described herein.
1: Gao JW, Zhan P, Qiu XY, Jin JJ, Lv TF, Song Y. Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials. Oncotarget. 2017 May 31;8(42):73258-73270. doi: 10.18632/oncotarget.18319. eCollection 2017 Sep 22. Review. 2: Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. J Natl Cancer Inst. 2017 Jun 1;109(6). doi: 10.1093/jnci/djw279. Review. doi: 10.1002/ijc.30691. Epub 2017 Mar 27. Review. doi: 10.1016/j.cllc.2017.01.013. Epub 2017 Feb 9. Review. doi: 10.1080/17476348.2017.1290526. Epub 2017 Feb 9. Review. doi: 10.15537/smj.2016.11.16267. Review. 7: Xu W, Gong Y, Kuang M, Wu P, Cao C, Chen J, Tang C. Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis. Clin Drug Investig. 2017 Feb;37(2):155-165. doi: 10.1007/s40261-016-0465-0. Review. doi: 10.1016/j.lungcan.2016.06.012. Epub 2016 Jun 14. Review. doi: 10.1136/bmjopen-2016-011714. Review.
合成参考文献
参考文献:10.1107/s1600536808011707 摘要:Selvanayagam S, Sridhar B, Ravikumar K. Erlotinib hydro-chloride: an anti-cancer agent. Acta Crystallogr Sect E Struct Rep Online. 2008 Apr 30;64(Pt 5):o931.